Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerGlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid Share XRelief for GSK as Tesaro’s Zejula hits the mark in ovarian cancerhttps://pharmaphorum.com/news/relief-for-gsk-as-tesaros-zejula-hits-the-mark-in-ovarian-cancer/
First-in-class diabetes drug recommended for FDA approvalAstraZeneca and Bristol-Myers Squibb have received a positive opinion from an FDA committee for dapagliflozin, a sodium-glucose cotransporter Share XFirst-in-class diabetes drug recommended for FDA approvalhttps://pharmaphorum.com/news/first-in-class-diabetes-drug-recommended-for-fda-approval/
